
UnitedHealth Group (UNH) received a 77% rating from Validea's Martin Zweig Growth Investor model, which targets stocks with accelerating earnings and sales, reasonable valuations, and low debt. While this score is just below the 80% threshold for 'some interest,' UNH demonstrated strengths in P/E ratio, sales growth, and current quarterly earnings, though it failed on certain earnings and revenue growth acceleration metrics. This assessment comes from a strategy based on Martin Zweig's methodology, which historically generated 15.9% average annual returns over 15 years.
UnitedHealth Group (UNH) scores a 77% on Validea's Martin Zweig Growth Investor model, positioning it as a large-cap growth stock with respectable, but not unequivocally strong, fundamentals according to this specific strategy. The score falls just short of the 80% threshold that typically indicates model interest. The company demonstrates strengths in several key areas, passing tests for its P/E ratio, sales growth rate, current and prior-year quarterly earnings, earnings persistence, long-term EPS growth, and insider transactions. However, the analysis reveals critical weaknesses that prevent a higher rating, specifically a failure to meet criteria related to growth acceleration. UNH did not pass on 'Revenue Growth in Relation to EPS Growth', 'Earnings Growth Rate for the Past Several Quarters', and 'EPS Growth for Current Quarter Must Be Greater Than the Historical Growth Rate'. This mixed result suggests that while UNH exhibits solid foundational profitability and valuation metrics, it currently lacks the accelerating momentum in both earnings and sales that the Zweig model prioritizes for top-tier growth investments.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment